Aptose Biosciences Company Profile (NASDAQ:APTO)

About Aptose Biosciences

Aptose Biosciences logoAptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: APTO
  • CUSIP:
Key Metrics:
  • Previous Close: $1.13
  • 50 Day Moving Average: $1.13
  • 200 Day Moving Average: $1.55
  • 52-Week Range: $0.83 - $4.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.97
  • P/E Growth: 0.00
  • Market Cap: $15.20M
  • Outstanding Shares: 13,455,000
  • Beta: 1.29
Profitability:
  • Return on Equity: -139.94%
  • Return on Assets: -121.78%
Debt:
  • Current Ratio: 5.29%
  • Quick Ratio: 5.29%
Additional Links:
Companies Related to Aptose Biosciences:

Analyst Ratings

Consensus Ratings for Aptose Biosciences (NASDAQ:APTO) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.75 (762.83% upside)

Analysts' Ratings History for Aptose Biosciences (NASDAQ:APTO)
Show:
DateFirmActionRatingPrice TargetDetails
1/23/2017Canaccord GenuityReiterated RatingBuy$7.00View Rating Details
11/16/2016RBC Capital MarketsLower Price TargetOutperform$18.00 -> $12.00View Rating Details
11/16/2016Royal Bank of CanadaLower Price TargetOutperform$18.00 -> $12.00View Rating Details
10/14/2016Roth CapitalReiterated RatingBuy$8.00View Rating Details
6/9/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Aptose Biosciences (NASDAQ:APTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2016Q415($0.28)($0.38)ViewN/AView Earnings Details
11/10/2015Q315($0.33)($0.27)ViewN/AView Earnings Details
8/4/2015Q215($0.36)($0.28)ViewN/AView Earnings Details
3/4/2015($0.31)($0.31)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aptose Biosciences (NASDAQ:APTO)
Current Year EPS Consensus Estimate: $-1.15 EPS
Next Year EPS Consensus Estimate: $-1.17 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.30)($0.29)($0.30)
Q2 20162($0.32)($0.31)($0.32)
Q3 20162($0.36)($0.24)($0.30)
Q4 20162($0.26)($0.24)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aptose Biosciences (NASDAQ:APTO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aptose Biosciences (NASDAQ:APTO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Aptose Biosciences (NASDAQ:APTO)
DateHeadline
News IconAnalyst Predictions Are In For Internap Corporation (NASDAQ:INAP) Aptose Biosciences Inc. (NASDAQ:APTO) - Rives Journal (NASDAQ:APTO)
rivesjournal.com - February 22 at 8:37 PM
News IconMarket Update: Watching Increased Volatility on Shares of Aptose Biosciences Inc. (NASDAQ:APTO) - Aiken Advocate (NASDAQ:APTO)
aikenadvocate.com - February 22 at 8:37 PM
News IconBroker Changes For Aptose Biosciences, Inc. (APTO) - NewsDen - NewsDen (NASDAQ:APTO)
newsden.net - February 21 at 3:51 PM
News IconBrokerage Expectations in Spotlight for Aptose Biosciences Inc. (NASDAQ:APTO) - Rockville Register (NASDAQ:APTO)
rockvilleregister.com - February 20 at 3:30 PM
News IconMarket Scout: Looking at the Levels for Aptose Biosciences Inc. (APTO) - Baxter Review (NASDAQ:APTO)
baxternewsreview.com - February 16 at 3:39 PM
News IconMarket Review: Indicator Watch for Aptose Biosciences Inc. (APTO) - Rives Journal (NASDAQ:APTO)
rivesjournal.com - February 14 at 2:06 AM
News IconAptose Biosciences Inc. (APTO) likely to see 4% move on its ... - Post Analyst (NASDAQ:APTO)
postanalyst.com - February 13 at 4:03 PM
News IconStock Levels in Review for Aptose Biosciences Inc. (APTO) - Davidson Register (NASDAQ:APTO)
davidsonregister.com - February 10 at 4:03 PM
News IconForward Earnings Estimate of Aptose Biosciences, Inc.(APTO) - Highland Mirror (NASDAQ:APTO)
www.highlandmirror.com - February 10 at 4:03 PM
News IconStock Update: Technicals in View for Aptose Biosciences Inc. (APTO) - Piedmont Register (NASDAQ:APTO)
piedmontregister.com - February 8 at 3:50 PM
News IconBrokers Add To Their Ratings On Aptose Biosciences, Inc. (APTO ... - NewsDen (NASDAQ:APTO)
newsden.net - February 4 at 8:40 PM
News IconTicker Watch: Technical Views on Shares of Aptose Biosciences Inc. (APTO) - Sherwood Daily (NASDAQ:APTO)
sherwooddaily.com - February 3 at 3:45 PM
News IconAptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day - P&T Community (NASDAQ:APTO)
www.ptcommunity.com - February 2 at 8:40 PM
News IconLooking at Moving Averages for Aptose Biosciences Inc. (APTO) - Sherwood Daily (NASDAQ:APTO)
sherwooddaily.com - February 2 at 3:38 PM
News IconTechnical Updates on Shares of Aptose Biosciences Inc (APS.TO) - Rives Journal (NASDAQ:APTO)
rivesjournal.com - February 2 at 3:38 PM
nasdaq.com logoAptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day - Nasdaq (NASDAQ:APTO)
www.nasdaq.com - February 2 at 3:38 PM
finance.yahoo.com logoAptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day (NASDAQ:APTO)
finance.yahoo.com - February 2 at 3:38 PM
News IconADX in View on Shares of Aptose Biosciences Inc. (APTO) - Sherwood Daily (NASDAQ:APTO)
sherwooddaily.com - February 1 at 8:47 PM
News IconDelving into Shares of Aptose Biosciences Inc. (NASDAQ:APTO) - Prospect Journal (NASDAQ:APTO)
prospectjournal.com - February 1 at 8:47 PM
News IconIndicator Level Summary for Aptose Biosciences Inc (APS.TO ... - Rives Journal (NASDAQ:APTO)
rivesjournal.com - January 31 at 8:51 PM
News IconPrimed for Breakout or Bust? A look at Aptose Biosciences Inc. (NASDAQ:APTO) - Prospect Journal (NASDAQ:APTO)
prospectjournal.com - January 31 at 8:51 PM
News IconTechnical Tracker: Watching Shares of Aptose Biosciences Inc (APS.TO) - Rives Journal (NASDAQ:APTO)
rivesjournal.com - January 31 at 2:43 AM
News IconBoom or Bust? Is there any value in Aptose Biosciences Inc. (NASDAQ:APTO) - Prospect Journal (NASDAQ:APTO)
prospectjournal.com - January 31 at 2:43 AM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Aptose Biosciences Inc. (NASDAQ:APTO) - Nelson Research (NASDAQ:APTO)
nelsonobserver.com - January 29 at 1:39 AM
News IconStock Momentum in Focus on Shares of Aptose Biosciences Inc. (APTO) - Sherwood Daily (NASDAQ:APTO)
sherwooddaily.com - January 27 at 9:26 PM
investopedia.com logoAptose Delays Lead Cancer Drug Development (APTO) (NASDAQ:APTO)
www.investopedia.com - January 27 at 4:25 PM
investopedia.com logoAptose Shifts Focus, Delays Cancer Drug Development (NASDAQ:APTO)
www.investopedia.com - January 27 at 4:25 PM
News IconStock Spotter: Review on Technical Levels for Aptose Biosciences Inc. (APTO) - Sherwood Daily (NASDAQ:APTO)
sherwooddaily.com - January 26 at 3:55 PM
News IconChecking Indicator Levels for Aptose Biosciences Inc (APS.TO) - Rives Journal (NASDAQ:APTO)
rivesjournal.com - January 26 at 3:55 PM
News IconCan This Stock Pick Up Any Momentum: Aptose Biosciences Inc. (NASDAQ:APTO) - Prospect Journal (NASDAQ:APTO)
prospectjournal.com - January 26 at 1:42 AM
News IconTrading Indicator Check on Aptose Biosciences Inc. (APTO) - Sherwood Daily (NASDAQ:APTO)
sherwooddaily.com - January 25 at 3:41 PM
News IconTechnical Indicator Review on Shares of Aptose Biosciences Inc. (APTO) - Sherwood Daily (NASDAQ:APTO)
sherwooddaily.com - January 24 at 3:45 PM
News IconInvestor Corner: Checking the Charts for Aptose Biosciences Inc (APS.TO) - Rives Journal (NASDAQ:APTO)
rivesjournal.com - January 24 at 3:45 PM
News IconStock on Trader's Radar: Aptose Biosciences Inc (NASDAQ:APTO) - Post Registrar (NASDAQ:APTO)
postregistrar.com - January 24 at 3:45 PM
streetinsider.com logoAptose Bio (APTO) to Prioritize Development of CG'806 and Temporarily Delay Clinical Activities with APTO-253 (NASDAQ:APTO)
www.streetinsider.com - January 23 at 8:50 PM
us.rd.yahoo.com logo7:02 am Aptose Biosciences will temporarily delay clinical activities with APTO-253 in order to elucidate the cause of recent manufacturing setbacks related to the intravenous formulation of APTO-253 (NASDAQ:APTO)
us.rd.yahoo.com - January 23 at 8:50 PM
News IconInvesting Focus: Indicators in View on Shares of Aptose Biosciences Inc. (APTO) - Sherwood Daily (NASDAQ:APTO)
sherwooddaily.com - January 23 at 3:40 PM
News IconShares Hitting The Skids, Bounding Lower Mid-Day: Aptose Biosciences Inc. (NASDAQ:APTO) - Wall Street Beacon (NASDAQ:APTO)
wsbeacon.com - January 23 at 3:40 PM
streetinsider.com logoForm 6-K Aptose Biosciences Inc. For: Jan 23 - StreetInsider.com (NASDAQ:APTO)
www.streetinsider.com - January 23 at 3:40 PM
News IconInvesting Focus: Indicators in View on Shares of Aptose Biosciences Inc (APS.TO) - Rives Journal (NASDAQ:APTO)
rivesjournal.com - January 21 at 2:36 AM
News IconEquity Research Analysts Peer Into Their Crystal Ball For Aptose Biosciences Inc. (NASDAQ:APTO) - Aiken Advocate (NASDAQ:APTO)
aikenadvocate.com - January 21 at 2:36 AM
News IconPrepping for a Big Move? Share Update on Aptose Biosciences Inc. (NASDAQ:APTO) - Prospect Journal (NASDAQ:APTO)
prospectjournal.com - January 21 at 2:36 AM
News IconAmplified Volatility Spotted in Shares of Aptose Biosciences Inc. (NASDAQ:APTO) - Wall Street Beacon (NASDAQ:APTO)
wsbeacon.com - January 21 at 2:36 AM
News IconChecking the Charts for Aptose Biosciences Inc (APS.TO) - Rives Journal (NASDAQ:APTO)
rivesjournal.com - January 19 at 9:35 PM
News IconTechnical Focus: Williams %R, ADX, and CCI Levels for Aptose Biosciences Inc (APS.TO) - Rives Journal (NASDAQ:APTO)
rivesjournal.com - January 18 at 9:12 PM
News IconInvestors Keen on a Bargain are Looking at Aptose Biosciences Inc. (NASDAQ:APTO) - Prospect Journal (NASDAQ:APTO)
prospectjournal.com - January 18 at 9:12 PM
News IconBreaking Short Interest: Could Aptose Biosciences Incorporated (NASDAQ:APTO) Change Direction After More Shorts? - Baxley Report (NASDAQ:APTO)
baxleyreport.com - January 14 at 3:35 PM
News IconHeady Investors are Taking a Look at Aptose Biosciences Inc. (NASDAQ:APTO) - Prospect Journal (NASDAQ:APTO)
prospectjournal.com - January 12 at 3:37 PM
News IconCalling all Bargain Hunters: Stock Update on Aptose Biosciences Inc. (NASDAQ:APTO) - Prospect Journal (NASDAQ:APTO)
prospectjournal.com - January 11 at 1:39 AM
News IconAt the Focal Point, Checking in on Aptose Biosciences Inc. (NASDAQ:APTO) - Prospect Journal (NASDAQ:APTO)
prospectjournal.com - January 10 at 3:38 PM

Social

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Where is Aptose Biosciences' stock going? Where will Aptose Biosciences' stock price be in 2017?

5 analysts have issued twelve-month price targets for Aptose Biosciences' shares. Their predictions range from $7.00 to $12.00. On average, they expect Aptose Biosciences' share price to reach $9.75 in the next year.

What are analysts saying about Aptose Biosciences stock?

Here are some recent quotes from research analysts about Aptose Biosciences stock:

  • According to Zacks Investment Research, "Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. " (11/17/2016)

  • Oppenheimer Holdings, Inc. analysts commented, "Aptose announced June 8 an agreement with CrystalGenomics for an exclusive global option and license for CrystalGenomics’ CG026806. CG026806 is a non- covalent small molecule inhibitor of Bruton’s tyrosine kinase (BTK), FMS-like tyrosine kinase 3 (FLT3) and the Aurora kinases (AURK). Aptose will make its decision on its option mid-2017 after executing IND-enabling studies. We reiterate our Outperform rating and $17 price target." (6/9/2016)

Who owns Aptose Biosciences stock?

Aptose Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (9.83%).

Who sold Aptose Biosciences stock? Who is selling Aptose Biosciences stock?

Aptose Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc..

How do I buy Aptose Biosciences stock?

Shares of Aptose Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aptose Biosciences stock cost?

One share of Aptose Biosciences stock can currently be purchased for approximately $1.13.

Aptose Biosciences (NASDAQ:APTO) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Aptose Biosciences (NASDAQ:APTO)

Earnings History Chart

Earnings by Quarter for Aptose Biosciences (NASDAQ:APTO)

Dividend History Chart

Dividend Payments by Quarter for Aptose Biosciences (NASDAQ:APTO)

Last Updated on 2/24/2017 by MarketBeat.com Staff